Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer. The agreement follows Phase 3 data that support clinical benefit in a difficult to treat patient group and inclusion of VEPPANU in NCCN breast cancer guidelines. The deal introduces a new commercialization pathway for VEPPANU and adds another partnership driven revenue channel for Pfizer. For investors...